Search Results

There are 15845 results for: content related to: Lichenoid drug eruption as a result of the recently released sulfonylurea glimepiride

  1. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial

    Diabetes, Obesity and Metabolism

    Volume 13, Issue 2, February 2011, Pages: 160–168, R. Arechavaleta, T. Seck, Y. Chen, K. J. Krobot, E. A. O’Neill, L. Duran, K. D. Kaufman, D. Williams-Herman and B. J. Goldstein

    Version of Record online : 27 DEC 2010, DOI: 10.1111/j.1463-1326.2010.01334.x

  2. Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trial

    Diabetes, Obesity and Metabolism

    Volume 17, Issue 3, March 2015, Pages: 276–284, B. Gallwitz, J. Rosenstock, S. Patel, M. von Eynatten, U. Hehnke, L. Mehlburger, K. A. Dugi and H.-J. Woerle

    Version of Record online : 9 JAN 2015, DOI: 10.1111/dom.12419

  3. Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride

    Clinical Pharmacology & Therapeutics

    Volume 69, Issue 4, April 2001, Pages: 194–200, Mikko Niemi, Janne T. Backman, Mikko Neuvonen, Jouko Laitila, Pertti J. Neuvonen and Kari T. Kivistö

    Version of Record online : 2 APR 2001, DOI: 10.1067/mcp.2001.114229

  4. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study

    Diabetes, Obesity and Metabolism

    Volume 12, Issue 9, September 2010, Pages: 780–789, D. R. Matthews, S. Dejager, B. Ahren, V. Fonseca, E. Ferrannini, A. Couturier, J. E. Foley and B. Zinman

    Version of Record online : 19 APR 2010, DOI: 10.1111/j.1463-1326.2010.01233.x

  5. You have free access to this content
    Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride

    British Journal of Clinical Pharmacology

    Volume 50, Issue 6, December 2000, Pages: 591–595, Mikko Niemi, Kari T. Kivistö, Janne T. Backman and Pertti J. Neuvonen

    Version of Record online : 24 DEC 2001, DOI: 10.1046/j.1365-2125.2000.00295.x

  6. Glimepiride reduces mononuclear activation of the redox-sensitive transcription factor nuclear factor-kappa B

    Diabetes, Obesity and Metabolism

    Volume 5, Issue 4, July 2003, Pages: 251–261, S. Schiekofer, G. Rudofsky Jr, M. Andrassy, J. Schneider, J. Chen, B. Isermann, M. Kanitz, S. Elsenhans, H. Heinle, B. Balletshofer, H.-U. Häring, E. Schleicher, P. P. Nawroth and A. Bierhaus

    Version of Record online : 6 JUN 2003, DOI: 10.1046/j.1463-1326.2003.00270.x

  7. You have full text access to this OnlineOpen article
    Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta-analysis

    International Journal of Clinical Practice

    Volume 69, Issue 3, March 2015, Pages: 292–304, JM. Amate, T. Lopez-Cuadrado, N. Almendro, C. Bouza, Z. Saz-Parkinson, R. Rivas-Ruiz and J. Gonzalez-Canudas

    Version of Record online : 16 FEB 2015, DOI: 10.1111/ijcp.12605

  8. Improved glycaemic control by addition of glimepiride to metformin monotherapy in Type 2 diabetic patients

    Diabetic Medicine

    Volume 18, Issue 10, October 2001, Pages: 828–834, G. Charpentier, F. Fleury, M. Kabir, L. Vaur and S. Halimi

    Version of Record online : 31 JUL 2009, DOI: 10.1046/j.1464-5491.2001.00582.x

  9. Glimepiride upregulates eNOS activity and inhibits cytokine-induced NF-κB activation through a phosphoinoside 3-kinase–Akt-dependent pathway

    Diabetes, Obesity and Metabolism

    Volume 11, Issue 2, February 2009, Pages: 143–149, T. Jojima, K. Suzuki, N. Hirama, K. Uchida and Y. Hattori

    Version of Record online : 28 JUN 2008, DOI: 10.1111/j.1463-1326.2008.00923.x

  10. You have full text access to this OnlineOpen article
    Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study

    Journal of Diabetes

    Volume 9, Issue 4, April 2017, Pages: 412–422, Sang Soo Kim, In Joo Kim, Kwang Jae Lee, Jeong Hyun Park, Young Il Kim, Young Sil Lee, Sung Chang Chung and Sang Jin Lee

    Version of Record online : 8 AUG 2016, DOI: 10.1111/1753-0407.12432

  11. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION)

    Diabetes, Obesity and Metabolism

    Volume 17, Issue 7, July 2015, Pages: 630–638, G. Schernthaner, S. Durán-Garcia, M. Hanefeld, G. Langslet, L. Niskanen, C. J. Östgren, E. Malvolti and E. Hardy

    Version of Record online : 7 APR 2015, DOI: 10.1111/dom.12461

  12. You have free access to this content
    Effect of metabolic inhibition on glimepiride block of native and cloned cardiac sarcolemmal KATP channels

    British Journal of Pharmacology

    Volume 136, Issue 5, July 2002, Pages: 746–752, C L Lawrence, R D Rainbow, N W Davies and N B Standen

    Version of Record online : 2 FEB 2009, DOI: 10.1038/sj.bjp.0704770

  13. A discriminating dissolution method for glimepiride polymorphs

    Journal of Pharmaceutical Sciences

    Volume 101, Issue 2, February 2012, Pages: 794–804, Rudy Bonfilio, Sumaia A. Pires, Leonardo M. B. Ferreira, Adélia E. de Almeida, Antônio C. Doriguetto, Magali B. de Araújo and Hérida R. N. Salgado

    Version of Record online : 3 NOV 2011, DOI: 10.1002/jps.22799

  14. Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring

    Diabetes, Obesity and Metabolism

    Volume 15, Issue 12, December 2013, Pages: 1111–1119, Y. L. He, G. Foteinos, S. Neelakantham, D. Mattapalli, K. Kulmatycki, T. Forst and A. Taylor

    Version of Record online : 14 JUL 2013, DOI: 10.1111/dom.12146

  15. Sitagliptin add-on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes

    International Journal of Clinical Practice

    Volume 66, Issue 5, May 2012, Pages: 465–476, S-I. Harashima, M. Ogura, D. Tanaka, T. Fukushima, Y. Wang, T. Koizumi, M. Aono, Y. Murata, M. Seike and N. Inagaki

    Version of Record online : 18 APR 2012, DOI: 10.1111/j.1742-1241.2012.02903.x

  16. You have free access to this content
    Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

    Diabetes, Obesity and Metabolism

    Volume 11, Issue 2, February 2009, Pages: 157–166, E. Ferrannini, V. Fonseca, B. Zinman, D. Matthews, B. Ahrén, S. Byiers, Q. Shao and S. Dejager

    Version of Record online : 29 DEC 2008, DOI: 10.1111/j.1463-1326.2008.00994.x

    Corrected by:

    Erratum

    Vol. 11, Issue 4, 405, Version of Record online: 24 FEB 2009

  17. Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial

    Diabetes, Obesity and Metabolism

    Volume 13, Issue 1, January 2011, Pages: 81–88, W. Yang, L. Chen, Q. Ji, X. Liu, J. Ma, N. Tandon, A. Bhattacharyya, A. Kumar, K.-W. Kim, K.-H. Yoon, O. M. Bech and M. Zychma

    Version of Record online : 28 NOV 2010, DOI: 10.1111/j.1463-1326.2010.01323.x

  18. No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects

    Diabetes, Obesity and Metabolism

    Volume 14, Issue 10, October 2012, Pages: 937–943, R. A. Smulders, W. Zhang, S. A. Veltkamp, J. van Dijk, W. J. J. Krauwinkel, J. Keirns and T. Kadokura

    Version of Record online : 7 JUN 2012, DOI: 10.1111/j.1463-1326.2012.01624.x

  19. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study

    Diabetes, Obesity and Metabolism

    Volume 17, Issue 7, July 2015, Pages: 689–698, G. Schernthaner, J. Rosas-Guzmán, F. Dotta, B. Guerci, R. Simó, A. Festa, J. Kiljański, M. Zhou and B. Gallwitz

    Version of Record online : 8 MAY 2015, DOI: 10.1111/dom.12471

  20. You have free access to this content
    Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin

    Diabetes, Obesity and Metabolism

    Volume 9, Issue 5, September 2007, Pages: 733–745, K. Hermansen, M. Kipnes, E. Luo, D. Fanurik, H. Khatami, P. Stein and Sitagliptin Study 035 Group

    Version of Record online : 26 JUN 2007, DOI: 10.1111/j.1463-1326.2007.00744.x